R-DXd has previously shown promising clinical results in platinum-resistant ovarian, peritoneal, and fallopian tube cancers.

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...

It’s akin to helping a flag football team bounce back from a blowout loss: You don’t retreat, you reframe—and build the ...

Eli Lilly's Orforglipron may become the first drug fast-tracked under the FDA's new program, promising quicker access for ...

Ways biopharma organizations and media brands can leverage coverage opportunities to help achieve respective audience goals ...

The quest to align cost with care, enhance data visibility, and shed the dependence on outdated revenue streams.

According to a report from AP News, 2 the group is expected to vote on whether to make changes to its advice on the COVID, hepatitis B, and chickenpox vaccines. Another item that’s expected to be on ...

Does FDA publish CRL? In Septemeber, 2025, FDA announced that it will publish CRL’s promptly after they are received by their ...

AstraZeneca pauses its £271 million Cambridge investment, reflecting growing concerns over the U.K.'s life sciences sector ...

Novartis partners with Monte Rosa Therapeutics in a $5.7 billion deal to develop innovative treatments for immune-mediated ...

The new administration has a different perspective of vaccines than the previous administration, causing confusion with the ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s return-to-office mandate from its CEO, the evolving COVID-19 vaccine landscape in 2025, and Capsida’s decision to halt a gene therapy ...